ImmunoGen (IMGN) is a creator and developer of antibody-drug conjugates (ADCs) aimed at improving cancer treatments. ImmunoGen aims to disrupt the progression of cancer through its conjugated targeted monoclonal antibodies. ImmunoGen’s lead ADC product candidate mirvetuximab soravtansine is in a Phase 3 study for folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer, and in Phase 1b/2 trial in combination regimens. ImmunoGen's novel IGN candidates for hematologic malignancies, IMGN779 and IMGN632, are in Phase 1 studies.
ImmunoGen reviewed its recent progresses . . .